$LLY

LLYEli Lilly and Company Common Stock

YouTube 频道最近怎么谈 Eli Lilly and Company(LLY)?

过去 7 天(截至 11-18),1 个 YouTube 频道谈到 Eli Lilly and Company(LLY),共 3 条。最近一条:Schwab Network,2026-11-16。

本窗口内的全部观点与内容

截至 11-18
11-16
Schwab Network发布 2026-11-16
《Adam Coons On Defense; "No Touch" on NVDA, Avoiding HD and LOW Pre-Earnings》
$LLY看涨
AI 摘要 · Eli Lilly 具有一定防御性;随着减肥药持续上市,接下来是 Retatrutide/GLP-3,它可能成为一款颠覆格局、消灭竞争的产品。说话者称 LLY 与 Google 一样有 10% 至 20% 的上涨空间,两者可因不同原因、在不同情境下跑赢。

像 Google 这样你喜欢的股票。它财报后确实出现了下跌,但整体处于某种上行趋势。还有 Eli Lily。你认为这两只股票都有 10% 到 20% 的上涨潜力吗?

Share like Google that you liked. I mean, it saw that decline after the earnings, but it was in a somewhat upward trend. And Eli Lily. Do you think both of these stocks have a 10 to 20% upside potential?

至于 Eli Lilly,它同样算是一只偏防御性的股票,但他们推出的产品,以及我们看到各种减肥药不断推出。我相信“Retatrotide”是下一个即将投产的产品。有人称它为“GLP-3”。

这款药很可能成为他们在这个领域的颠覆性产品,并可能淘汰其余竞争对手。

As for Eli Lilly, it is once again a somewhat defensive stock , but the products they are putting forward and we see a continuation of the introduction of various obesity drugs.

I believe "Retatrotide" is next in the production line. Some people call it "GLP-3". This drug is likely to be a game-changer for them in this field, and may eliminate the rest of the competition.

11-13
Schwab Network发布 2026-11-13
《PPI Mostly Cool, AI at "Crossroads" Amid NVDA CEO Search》
$LLY看涨
AI 摘要 · Eli Lilly 是一个高溢价成长故事:在表现出色的一年里上涨35%,也是医疗保健板块上涨行情的领跑者之一;它凭借三款领先的 GLP1 产品抓住了医疗保健领域最大的机会,有利的人口结构持续为强劲的研发管线提供顺风,因此其高溢价估值是合理的。

Eli Lilly 是你名单上的名字之一。我猜这是对 GLP1 领域的押注,但请给我们讲讲你的投资逻辑。正是如此。Eli Lilly 今年表现很好,上涨了35%,确实是这轮医疗保健行情中的领跑者之一。

正如你提到的,他们凭借三款领先的 GLP1 产品,抓住了当前医疗保健领域最大的机会。

Eli Lilly is one of those names on your list. I'm betting this is a bet on the GLP1 space, but walk us through your thesis here. Exactly. You know, Eli Lilly's had a great year up 35% and really one of the leaders of that healthcare run.

As you mentioned, they've been able to capitalize on, you know, really the the biggest opportunity right now in healthcare with their three leading GLP1 products.

11-12
Schwab Network发布 2026-11-12
《The Big 3: JNJ, LLY, AAPL》
$LLY看涨
AI 摘要 · Eli Lilly 技术面强劲,说话者预计将出现一段有节制的上行:较快的移动平均线有利于多头,但该股尚未令人信服地突破 14.50 的上限,且 RSI 显示看跌背离。他更倾向于用期权结构在捕捉上行空间的同时限制下行风险,目标 1560–1600,理想涨幅 8–10%;该股估值偏高、期权操作难度大,而医疗保健板块到 2027 年应保持相对强势。

你的下一个选择也在医疗保健板块。我们有 Eli Lilly。我是说,也许 Eli Lilly 的图表在技术面上更清晰。那么,你对 Lilly 的前景怎么看?观点类似。从技术角度看,动量肯定是在的。

但同样,我从根本上认为,随着我们进入2027年,医疗保健板块将继续展现出相对强度。这是一只昂贵的股票。由于股票的规模和期权的成本,很难在它上面构建期权头寸。不过,我仍然相信有机会,这就是为什么我今天看交易示例时,重点是在期权上构建一笔交易。

因此,在某种程度上,我们识别下行风险,同时具备捕捉价格上涨的能力。

Your next choice is also in the healthcare sector. We have Eli Lilly. I mean, perhaps Eli Lilly's chart is more technically clear. So , what is your outlook for Lilly? A similar view.

The momentum is definitely there from a technical standpoint. But again, I fundamentally believe that the healthcare sector will continue to demonstrate relative strength as we enter 2027.

It is an expensive stock. It is difficult to structure options positions on it due to the size of the stock and the cost of the options as well. However, I still believe there are opportunities, and that's why when I looked at the trading example today, the focus was on structuring a deal around options.

Therefore, to some extent, we identify downside risks with the ability to capture upward price movements.

已显示 3 / 本页 3 条
看这只股票的全部记录